BRAIN AG (together with its subsidiaries the “BRAIN Group” or
“BRAIN”) has concluded an agreement with Wilde Cosmetics GmbH,
Oestrich-Winkel, on the sale of all shares in the loss-making Monteil
Cosmetics International GmbH (“Monteil”) held by BRAIN to Wilde
Cosmetics GmbH. The transaction will be completed on 30 June 2019. The
contracting parties have agreed not to disclose financial details.
Cosmetics International GmbH, based in Düsseldorf, is represented as a
brand company in the cosmetics end customer business (B2C). It has been
part of the BRAIN Group since 2011. Most recently, BRAIN AG held 68.3%
of the Monteil shares, while Wilde Cosmetics GmbH acted as a minority
shareholder. The sale of the loss-making investment will unburden the
BRAIN Group both financially and in terms of capacity and allow it to
concentrate fully on the further expansion of the product-scalable B2B
“The focus of the BRAIN Group is on growing the product
business with industrial partners. The companies in the BRAIN Group are
now fully specialized in R&D and B2B business. This is where we see
the absolute strengths of the BRAIN Group, which we are continuously
expanding”, says Dr. Jürgen Eck, CEO of BRAIN AG.
“We have taken a
further step towards consistently implementing our strategy. The pure
B2B cosmetics business is and will remain part of the growth strategy”,
says Ludger Roedder, CBO of BRAIN AG.
“The sale of the Monteil
shares has no impact on the forecasts of BRAIN AG for the current
2018/19 financial year. Rather, we confirm the objective of achieving a
double-digit growth rate in total operating performance and improved
EBITDA at Group level”, adds Manfred Bender, CFO of BRAIN AG.